| Literature DB >> 31272382 |
Jemma Hudson1, Shona Fielding2, Craig R Ramsay3.
Abstract
BACKGROUND: Randomised controlled trials (RCTs) are considered the gold standard when evaluating the causal effects of healthcare interventions. When RCTs cannot be used (e.g. ethically difficult), the interrupted time series (ITS) design is a possible alternative. ITS is one of the strongest quasi-experimental designs. The aim of this methodological study was to describe how ITS designs were being used, the design characteristics, and reporting in the healthcare setting.Entities:
Keywords: Healthcare interventions; Interrupted time series; Quasi-experimental
Mesh:
Year: 2019 PMID: 31272382 PMCID: PMC6609377 DOI: 10.1186/s12874-019-0777-x
Source DB: PubMed Journal: BMC Med Res Methodol ISSN: 1471-2288 Impact factor: 4.615
Fig. 1PRISMA diagram
ITS study characteristics described in the scientific abstract
| Method of analysis given | 66 (57) |
| Number of pre-intervention points stated | 34 (29) |
| Number of post-intervention points stated | 33 (28) |
| Main results reported | 85 (73) |
Values are n (%)
Study characteristics of included ITS
| N = 116 | |
|---|---|
| Study definition provided in at least title, abstract or main paper | 74 (64) |
| Title, abstract, and main paper | 9 (12) |
| Abstract and main paper | 16 (22) |
| Title and main paper | 17 (23) |
| Title and abstract | 1 (1) |
| Title | 5 (7) |
| Abstract | 7 (9) |
| Main paper | 19 (26) |
| Country of study | |
| USA | 39 (34) |
| UK | 18 (16) |
| Asia | 18 (16) |
| Europe | 14 (12) |
| Canada | 11 (9) |
| Australia | 7 (6) |
| Africa | 6 (5) |
| Middle East | 2 (2) |
| Panama | 1 (1) |
| Type of intervention | |
| Programs (e.g. multifaceted) | 41 (35) |
| Policy (e.g. regulatory) | 32 (28) |
| Health systems | 25 (22) |
| Guidelines | 19 (16) |
| Financial | 19 (16) |
| Behavioural | 15 (13) |
| Sales and dispensing | 1 (1) |
| Level of intervention | |
| Hospital | 73 (63) |
| Hospital department | 22 (19) |
| Individual | 17 (15) |
| GP practices | 3 (3) |
| Pharmacy | 1 (1) |
| Participants | |
| Health professional | 92 (79) |
| Disease | 30 (26) |
| Occupational | 3 (3) |
| Population | 1 (1) |
| Data source | |
| Hospital data | 64 (55) |
| Health records | 27 (23) |
| National data | 26 (22) |
| Insurance data | 11 (9) |
| Other | 3 (3) |
| Type of outcome | |
| Continuous | 66 (57) |
| Rate | 38 (33) |
| Binary | 11 (9) |
| Count | 1 (1) |
| Frequency | |
| Monthly | 74 (64) |
| Quarterly | 23 (20) |
| Yearly | 14 (12) |
| Weekly | 2 (2) |
| Othera | 3 (3) |
| Number of data points - median (25th,75th centile) | |
| Pre-intervention | 18 (12–32) |
| Post-intervention | 19 (12–34) |
| Ratio of pre/ post-intervention data points | 1 (1–2) |
| Transition period ( | 3 (1–9) |
| Other data points that were accounted for ( | 2 (2–8) |
Values are n (%) unless otherwise stated. a 90 day periods; five times over two weeks before and after; daily
Abbreviations: US United States, UK United Kingdom
Methodology characteristics in included ITS
| Description of the analysis | 115 (99) |
| Segmented regression | 90 (78) |
| ARIMA model | 15 (13) |
| Generalised estimating equations | 7 (6) |
| Change-point analysis | 2 (2) |
| Mixed model | 1 (1) |
| Autocorrelation was considered | 63/115 (55) |
| Method used to test for autocorrelationa | |
| Durbin Watson | 22 (35) |
| Autocorrelation function | 13 (21) |
| Partial autocorrelation function | 11 (17) |
| Ljung-Box | 3 (5) |
| Examination of residuals | 2 (3) |
| Portmanteau tests | 2 (3) |
| Autocorrelation probability | 1 (2) |
| No test performed | 23 (37) |
| Autocorrelation present if a test was performed | |
| No | 12 (30) |
| Yes | 25 (63) |
| Not stated | 3 (8) |
| Method used to adjust for autocorrelation | |
| Autoregressive error term | 14 (29) |
| Prais-winsten regression model | 8 (17) |
| Differencing | 3 (6) |
| Newey-west standard errors | 2 (4) |
| Yule-walker regression model | 2 (4) |
| Did not specify | 19 (40) |
| Order of autocorrelation | N = 48 |
| 1 | 8 (17) |
| 2 | 3 (6) |
| 3 | 2 (4) |
| 4 | 1 (2) |
| 5 | 1 (2) |
| Did not specify | 33 (69) |
| Nonstationary was considered | 9/115 (8) |
| Method used to test for non-stationary | |
| Dicky-Fuller | 5 (56) |
| ACF and PACF | 2 (22) |
| Significance testing | 1 (11) |
| Not stated | 1 (11) |
| Nonstationary was present if a test was performed | |
| No | 4 (50) |
| Yes | 3 (38) |
| Not stated | 1 (13) |
| Method used to adjust for nonstationary | N = 3 |
| Differencing | 2 (67) |
| Within the ARIMA model | 1 (33) |
| Seasonality was considered | 28/115 (24) |
| Method used to test for seasonality | |
| ACF PACF | 5 (18) |
| Regression diagnostic tests | 1 (4) |
| Dicky-Fuller | 1 (4) |
| Just stated a test was performed | 4 (14) |
| No formal test | 17 (61) |
| Seasonality present if a test was performed | |
| No | 6 (86) |
| Yes | 1 (14) |
| Method used to adjust for seasonality | |
| Covariate | 7 (32) |
| Seasonal ARIMA | 1 (5) |
| Differencing | 1 (5) |
| Not stated | 13 (59) |
| Sample size description |
|
| No | 108 (94) |
| Yes | 7 (6) |
Values are n (%). Abbreviations: ARIMA, Autoregressive integrated moving average; GEE generalized estimating equation; ACF, autocorrelation function; PACF Partial autocorrelation function
ITS study effect sizes reported
| Relative effects | |
| Relative slope | 13 (11) |
| Relative to: | |
| Baseline trend | 8 (62) |
| Not stated | 5 (38) |
| CI/SE reported | 1 (8) |
| | 2 (15) |
| Relative level | 16 (14) |
| Relative to: | |
| Baseline trend | 13 (81) |
| Last pre-intervention data point | 1 (6) |
| Not stated | 2 (13) |
| CI/SE reported | 8 (50) |
| p-value reported | 6 (38) |
| Absolute effects | |
| Change in slope | 97 (84) |
| CI/SE reported | 74/97 (76) |
| p-value reported | 84/97 (87) |
| Change in level | 81 (70) |
| Immediate | 75/81 (93) |
| CI/SE reported | 60/75 (80) |
| p-value reported | 67/75 (89) |
| Other level effects | 17/81 (21) |
| CI/SE reported | 11/17 (65) |
| p-value reported | 8/17 (47) |
| Other estimates reported | |
| Intercept | 40 (34) |
| Pre-slope trend | 74 (64) |
| Post-slope trend | 15 (13) |
Values are n (%). Abbreviations: CI Confidence interval, SE Standard error
Discussion of findings in ITS studies
| Key results summarised with reference to objectives | |
| No | 2 (2) |
| Yes | 113 (97) |
| Some | 1 (1) |
| Discussion of bias | 65 (56) |
| Weaknesses/limitations | 98 (84) |
| Strengths | 39 (34) |
Values are n (%)